Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Final ASCEND study data: Acalabrutinib beat standard of care for r/r CLL

Key clinical point: Acalabrutinib has favorable efficacy versus standard of care for relapsed or refractory chronic lymphocytic leukemia.

Major finding: The estimated 18-month progression-free survival was 82% versus 48% with acalabrutinib versus standard of care.

Study details: Final results from the phase 3 ASCEND trial of 310 patients.

Disclosures: This study was sponsored by Acerta Pharma. Dr. Ghia reported consulting or advisory roles, grant or research funding, and/or honoraria from a variety of pharmaceutical companies.


Ghia P et al. SOHO 2020, Abstract CLL-091.